UCHL1 and coronary artery disorder: The findings of the present study implicate that the UCHL1 inhibition probably can be tolerated by normal hearts because the complete loss of function of UCHL1 in cardiomyocytes did not show discernible abnormality; however, such a treatment should be watched for cardiotoxicity if the subject has cardiac co-morbidities because UCHL1 deficiency does impair cardiac proteostasis when the heart is under a stress condition such as ischemic heart disease.